Stem Cell ACE2 Composition for Preventing SARS-CoV-2 Binding

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing methods, including those using mesenchymal stem cells, do not effectively prevent COVID-19 infection in healthy individuals, and the therapeutic mechanisms and active ingredients are not sufficiently elucidated.

Innovation Solution

A composition containing a culture supernatant or microparticles derived from dental pulp-derived, adipose-derived, or umbilical cord-derived stem cells, which express ACE2, is used to inhibit the binding of viruses using ACE2 as a receptor, such as SARS-COV-2, thereby preventing infection in healthy individuals.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If mesenchymal stem cells are used to treat COVID-19 patients, then therapeutic effect is improved, but prevention capability for healthy individuals is insufficient

Engineering Contradiction:

Improvetherapeutic effectVSAvoidprevention capability

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent extracts the active ingredient (ACE2) from mesenchymal stem cells and uses it in purified form for prevention purposes. This extraction allows the preventive application to use only the necessary component without the limitations of whole cell therapy, enabling both therapeutic and preventive uses.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent applies preliminary action by administering ACE2 to healthy individuals before virus exposure to prevent infection. This preventive approach differs from treating established disease, allowing the composition to block viral entry before infection occurs.

Inventive Principle:

Principle #10Preliminary action

2Reliability

If ACE2-positive composition is administered to healthy individuals for prevention, then binding inhibition is improved, but risk of viral entry into administered composition is introduced

Engineering Contradiction:

Improvebinding inhibitionVSAvoidviral entry risk

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses ACE2 as an intermediary substance that binds to the virus in the composition rather than to human cells. This intermediary approach allows the ACE2 in the administered composition to act as a decoy, capturing the virus and preventing it from entering human cells while maintaining safety.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Reliability

If ACE2 is administered to prevent virus binding, then binding inhibition is improved, but ACE2 is consumed in the process

Engineering Contradiction:

Improvebinding inhibitionVSAvoidACE2 consumption

Core Design Contradiction:

ReliabilityVSLoss of substance

Solution Approach 1:

The patent addresses ACE2 consumption by changing the concentration parameter of the administered composition. By formulating the composition with sufficient ACE2 concentration, the patent ensures that the binding inhibition effect is maintained throughout the dosing period despite ACE2 being consumed during virus neutralization.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The composition effectively inhibits the binding of SARS-COV-2 to ACE2, providing a preventive measure against COVID-19 infection in healthy individuals.

Implementation Method 1

SARS-COV-2, like SARS-COV, binds to cells having angiotensin-converting enzyme 2 (ACE2) (alveolar type II cells, capillary endothelial cells and the like)

Methodology Applied

Scientific EffectVirus-receptor binding: Adsorption

Data Source

PatentUS20260091066A1Method for preventing infection of a healthy person or a healthy animal with a virus that uses ace2 as a receptor, binding inhibitor and medical device

Publication Date: 2026.04.02 DEXON PHARM INC

AI summary

A composition containing a culture supernatant of dental pulp-derived stem cells, adipose-derived stem cells, umbilical cord-derived stem cells or immortalized stem cells thereof in which the composition contains angiotensin-converting enzyme 2 (ACE2) and is used for administration to a healthy person or a healthy animal for preventing infection of the healthy person or the healthy animal with a virus that uses ACE2 as a receptor can be used as a medicine for preventing infection with a virus that uses ACE2 as a receptor, such as COVID-19, or the like when administered to a healthy person or a healthy animal.